Sorrento Therapeutics Announces $25 Million Registered Direct Offering
October 07, 2019 14:35 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn...
Scilex Holding Announces Strong ZTlido Sales Growth After Successful Post-Merger Integration
June 05, 2019 07:00 ET
|
Sorrento Therapeutics, Inc.
ZTlido® gross sales grew from approximately $1 million in March to $2.4 million in April and $3.3 million in MaySP-102 pivotal phase 3 trial remains on track for completion in H1 2020ZTlido® 5.4% (3 X...
Sorrento Therapeutics Closes Five-Year Term Loan Financing for Up to $150 Million
November 08, 2018 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE), a clinical-stage immunotherapy biotech company, announces the closing of a debt financing for up to $150...
Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases
November 06, 2018 08:01 ET
|
Sorrento Therapeutics, Inc.
Two out of four patients showed complete resolution of liver metastases on PET scanMedian overall survival (OS) 8.3 months and mean OS 9.8 months, compared to the standard of care 3 to 6 monthsMeeting...
Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma
November 01, 2018 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an innovative immunotherapy company, announced today that the first patients were dosed in a Phase 1 study to...
Sorrento Therapeutics to Present at FB Riley and HC Wainwright Sept 2018 Healthcare Conferences in NYC (NY)
September 02, 2018 13:19 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 02, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will be participating in upcoming...
1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations
August 13, 2018 04:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that the first enrolled patient in the phase 1b study of its non-opioid, afferent nerve...
Sorrento Therapeutics Welcomes Jiong Shao as Chief Financial Officer and Reaffirms Intent to Seek Nasdaq/HKSE Dual Listing in 2018
March 19, 2018 08:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, March 19, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento") announced today that it appointed Mr Jiong Shao as Executive Vice President and Chief Financial...
HCI Group Real Estate Division Acquires New Shopping Center
September 15, 2016 08:00 ET
|
HCI Group, Inc.
TAMPA, Fla., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Greenleaf Capital, the real estate division of HCI Group, Inc. (NYSE:HCI), has acquired a newly built shopping center located in Sorrento, Florida,...